Clinical Focus
Business Focus
Spotlight
Subscribe
CE/CME
- Clinical Technology
- Adult Immunization
- Hepatology
- Pediatric Immunization
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Infectious Disease
- Obesity Medicine
- Rheumatology
- Nephrology
- Neurology
- Pulmonology
Older Approaches to Topical Treatment of Atopic Dermatitis
Panelists discuss how older topical treatments such as corticosteroids, calcineurin inhibitors, and crisaborole have limited efficacy with prolonged use. Corticosteroids cause skin thinning and systemic absorption on large body surface area (BSA). Calcineurin inhibitors and crisaborole show modest efficacy, with application site reactions.
EP: 1.Diagnosing and Defining Severity of Atopic Dermatitis
Now Viewing
EP: 2.Older Approaches to Topical Treatment of Atopic Dermatitis
EP: 3.New Nonsteroidal Topical Treatment Options for Atopic Dermatitis
EP: 4.Long-Term Use of Topical Treatments in Atopic Dermatitis
EP: 5.Addressing Itch and Quality of Life for Patients With Atopic Dermatitis
EP: 6.Importance of Patient Education and Multidisciplinary Communication
Video content above is prompted by the following:
- What are some of the common uses as well as limitations of older topical treatment options (topical corticosteroids, calcineurin inhibitors, crisaborole)?
- Adverse effects, BSA limitations, long-term effects of steroids
- Discuss your approach to treatment for mild to moderate atopic dermatitis.
Related Videos
Related Content
Lebrikizumab Demonstrates Efficacy, Safety in Patients With Skin of Color With AD
June 11th 2025Article
RAD 2025. Lebrikizumab improved skin clearance, itch, and pigmentation in patients with skin of color and atopic dermatitis, with strong safety data through 24 weeks, according to late-breaking data.
